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Aim: To compare the in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial
agents against Gram-positive clinical isolates from skin and soft tissue infections. Materials & methods: Iso-
lates were collected in two studies: 1097 isolates from 49 centers during 2009–2010 and 1031 isolates from
ten centers during 2014. Minimum inhibitory concentrations were determined for 18 and 11 antimicro-
bials in these studies, respectively, using standard broth microdilution methods. Isolates were stratified by
species and methicillin susceptibility/resistance and/or levofloxacin susceptibility/nonsusceptibility status.
Results: Ozenoxacin exhibited high in vitro activity against Staphylococcus aureus and coagulase-negative
staphylococci isolates in both studies. Ozenoxacin was also highly active against Streptococcus pyogenes
and Streptococcus agalactiae isolates. Conclusion: Ozenoxacin is a potent antimicrobial agent against
staphylococci and streptococci.
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Impetigo is a common bacterial skin infection affecting both children and adults although it is more prevalent
in children. Infection with Staphylococcus aureus or Streptococcus pyogenes causes the nonbullous type of impetigo
which occurs in around 70% of cases, whereas S. aureus exclusively causes bullous impetigo, with the production
of exfoliative toxins [1–3].
Topically administered antibacterial agents, mupirocin and fusidic acid, are commonly used to treat impetigo,
although retapamulin is a more recent alternative [4,5]. The most recent topical option and the only compound
with bactericidal properties is the nonfluorinated quinolone, ozenoxacin [6], which demonstrated clinical benefit in
a recent Phase III trial [7]. The results of a second Phase III trial which is currently being published showed similar
clinical and microbiological results (ClinicalTrials.gov identifier: NCT02090764) [8].
During the development of ozenoxacin, surveillance studies addressing its antimicrobial activity in comparison
with other antimicrobials were conducted. In this article, the in vitro activity of ozenoxacin against Gram-positive
clinical isolates recovered from skin and soft-tissue infections (SSTIs) is compared with a panel of antibacterial
agents. More than 2000 isolates were collected in two worldwide studies from 2009 to 2010, and during 2014.
The isolates include the causative microorganisms of impetigo, S. aureus and S. pyogenes, and coagulase-negative
staphylococci which are the most common microorganisms on normal skin flora, with Staphylococcus epidermidis
being the predominant species [3]. Comparisons with a wide range of antimicrobial agents were made using
the minimum inhibitory concentration (MIC) value, which is also useful for assessing antimicrobial phenotypic
resistance [9].
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Materials & methods
Study 1: evaluation of the in vitro activity of ozenoxacin & comparative antimicrobial agents
against Gram-positive clinical isolates collected during 2009 & 2010
The in vitro activity of ozenoxacin was evaluated against Gram-positive isolates collected from 49 centers in the
Czech Republic (n = 3), Germany (n = 3), The Netherlands (n = 3), Romania (n = 3), South Africa (n = 3), Spain
(n = 4) and the USA (n = 30). Organisms were obtained randomly from uncomplicated SSTIs (uSSTIs) and/or
complicated SSTIs (cSSTIs) during 2009 and 2010. A total of 1097 isolates were collected from participating
sites, with 50.0% originating from inpatients (n = 548) and 49.9% (n = 547) from outpatients; the origin of two
isolates was not recorded. Isolates were classified as S. aureus (n = 486), S. epidermidis (n = 190), other coagulase-
negative Staphylococcus (CNS) species (n = 37), S. pyogenes (n = 217), Streptococcus agalactiae (n = 37), Streptococcus
pneumoniae (n = 29) and Corynebacterium spp. (n = 52). Other isolates were Micrococcus spp. (n = 7), Lactobacillus
spp. (n = 7), Group G Streptococcus (n = 19), Group C Streptococcus (n = 9), and Brevibacterium spp. (n = 3); plus
Enterococcus faecalis (n = 2), Kocuria kristinae (n = 1) and Rothia mucilaginosa (n = 1).
S. aureus was identified by Gram stain, catalase and DNAse production, and the staphylococcal latex agglu-
tination test. In addition, cefoxitin susceptibility was performed to determine methicillin resistance. Identifica-
tion of coagulase-negative staphylococci was performed using Gram stain, catalase and DNAse production, the
staphylococcal latex agglutination test, API Identification Systems or mass spectrometry (matrix assisted laser
desorption/ionization–time of flight mass spectrometry [MALDI–TOF MS], Bruker Daltonics, Bremen, Ger-
many). Cefoxitin susceptibility was also performed. Groups A, B, C and G streptococci were identified using Gram
stain, catalase production and Lancefield grouping. Identification of S. pneumoniae used Gram stain, optochin
susceptibility and bile solubility. Identification of Corynebacterium spp., Micrococcus spp. and Lactobacillus spp.
used Gram stain, catalase production and identification by API Identification Systems or MALDI-TOF MS.
MIC was determined by the broth microdilution method as recommended by the Clinical and Laboratory
Standards Institute (CLSI) [10]. MIC50 and MIC90 values were calculated for each antimicrobial agent.
For determination of MICs, the same range of concentrations for each antimicrobial were tested against species
of Staphylococcus, Corynebacterium, Micrococcus and Lactobacillus (group 1 species); with the tested MIC range
often differing for Streptococcus species. Respective tested MIC ranges for group 1 species and Streptococcus species
were: ozenoxacin (0.001–2; 0.001–2 mg/l), amoxicillin-clavulanate (0.03–32; 0.008–16 mg/l), ceftriaxone (0.03–
64; 0.03–64 mg/l), cefuroxime (0.03–64; 0.015–16 mg/l), ciprofloxacin (0.002–4; 0.03–32 mg/l), clindamycin
(0.03–64; 0.015–32 mg/l), daptomycin (0.015–32; 0.015–32 mg/l), erythromycin (0.03–64; 0.015–32 mg/l),
fusidic acid (0.03–64; 0.03–64 mg/l), gentamycin (0.03–32; 0.03–64 mg/l), levofloxacin (0.004–8; 0.03–64 mg/l),
linezolid (0.015–32; 0.015–32 mg/l), mupirocin (0.03–64; 0.03–64 mg/l), neomycin (0.03–64; 0.03–64 mg/l),
penicillin G (0.03–64; 0.008–16 mg/l), retapamulin (0.008–16; 0.008–16 mg/l), tetracycline (0.03–64; 0.03–
64 mg/l) and vancomycin (0.03–32; 0.03–32 mg/l). Two quality-control strains (S. aureus ATCC 29213 and S.
pneumoniae ATCC 49619) were also included in the study.
Susceptibility results were interpreted using breakpoints set by the CLSI [10,11]. Nevertheless, European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) [12] or British Society for Antimicrobial Chemother-
apy [13] breakpoints were used for different antimicrobials: staphylococci and fusidic acid [13]; S. pneumoniae
and ciprofloxacin [12]; staphylococci and mupirocin [13]; and Corynebacterium species for amoxicillin-clavulanate,
cefuroxime and levofloxacin [12]. No breakpoints are yet defined by the CLSI or EUCAST for ozenoxacin.
Study 2: evaluation of the in vitro activity of ozenoxacin & comparative antimicrobials against
relevant clinical isolates collected during 2014
A total of 1031 clinical isolates of S. aureus (n = 504), coagulase-negative staphylococci (n = 315), S. pyogenes
(n = 124) and S. agalactiae (n = 88) were collected from January to December 2014 at ten participating centers
located in Argentina, Brazil, Colombia, Germany, Romania, South Africa, Spain, Sweden and at two sites in the
USA. Species in the coagulase-negative staphylococci group were Staphylococcus capitis (n = 17), Staphylococcus caprae
(n = 4), Staphylococcus cohni (n = 1), S. epidermidis (n = 195), Staphylococcus haemolyticus (n = 27), Staphylococcus
hominis (n = 12), Staphylococcus intermedious (n = 3), Staphylococcus lugdunensis (n = 42), Staphylococcus saprophyticus
(n = 2), Staphylococcus simulans (n = 4) and Staphylococcus warneri (n = 8). Two quality-control strains (S. aureus
ATCC 29213 and S. pneumoniae ATCC 49619) were also included in the study.
All isolates were tested for susceptibility to amoxicillin-clavulanate, ciprofloxacin, clindamycin, erythromycin,
fusidic acid, mupirocin, levofloxacin, ozenoxacin, penicillin and vancomycin using prepared dry panels (Sensititre™,
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Thermo Fisher Scientific). They were prepared using the broth microdilution method as recommended by the
CLSI [10]. The range of concentrations tested were: ozenoxacin (0.001–16 mg/l), amoxicillin-clavulanate (4/2–
8/2 mg/l), ciprofloxacin (0.015–16 mg/l), clindamycin (0.015–16 mg/l), erythromycin (0.015–16 mg/l), fusidic
acid (0.015–16 mg/l), levofloxacin (0.015–16 mg/l), mupirocin (0.015–256 mg/l), penicillin G (0.12–0.25 mg/l),
retapamulin (0.015–1 mg/l) and vancomycin (0.5–2 mg/l). Susceptibility results were interpreted using an approach
that was similar to the previous study but using CLSI and EUCAST documents from 2014.
Results
Source of isolates & quality control results
Isolates in study 1 were recovered from skin (n = 541; 49.3%), wounds (n = 300; 27.3%), abscesses (n = 98; 8.9%),
tissue (n = 45; 4.1%), blood (n = 40; 3.6%) or other (n = 73; 6.7%). SSTIs were further categorized as cSSTI,
uSSTI or unknown. The proportion of skin isolates (expressed as a percentage of the total sample) categorized as
cSSTI, uSSTI and unknown were 18.3% (n = 201), 23.4% (n = 257) and 7.6% (n = 83), respectively. Respective
proportions by site of recovery were, for wound: 10.8% (n = 118), 8.2% (n = 92) and 8.4% (n = 90); for abscess:
2.6% (n = 28), 1.9% (n = 49) and 4.5% (n = 21); for tissue: 2.5% (n = 27), 1.5% (n = 2) and 0.2% (n = 16); for
blood: 1.3% (n = 14; 1.7% (n = 7) and 0.6% (n = 19); and for other: 2.2% (n = 24), 1.5% (n = 33) and 3.0%
(n = 16).
Isolates in study 2 were recovered from wounds (n = 410; 39.8%), abscesses (n = 163; 15.8%), skin (n = 20;
1.9%), acne (n = 11; 1.1%), tissues (n = 8; 0.8%) and nonspecified SSTIs (n = 419; 40.6%).
All quality control results were within the quality control ranges specified by CLSI Documents M100-S20
(2011) [14] and M100-S24 (2014) [15].
S. aureus
Study 1
Table 1 shows MIC50 and MIC90 values for ozenoxacin and 18 comparator antimicrobial agents against S. aureus
isolates, which were also stratified by methicillin (-susceptible S. aureus [MSSA]; -resistant S. aureus [MRSA]) and
levofloxacin susceptibility. Ozenoxacin was highly active against the 486 S. aureus isolates tested, with a MIC50 of
0.004 mg/l and a MIC90 of 0.25 mg/l. For levofloxacin-nonsusceptible S. aureus isolates (n = 168; levofloxacin
MIC50 = 8 mg/l and MIC90 = 16 mg/l), the ozenoxacin MIC50 was 0.12 mg/l and the MIC90 was 0.5 mg/l.
Ozenoxacin had lower MIC values (MIC50 = 0.004 mg/l and MIC90 = 0.004 mg/l) against levofloxacin-susceptible
S. aureus isolates (n = 312; levofloxacin MIC50 = 0.25 mg/l and MIC90 = 0.25 mg/l; Table 1). The MIC90 of
ozenoxacin (0.25 mg/l) was comparable to those of fusidic acid, mupirocin and retapamulin (all 0.25 mg/l) against
all S. aureus isolates tested. In contrast, ciprofloxacin (8 mg/l) and levofloxacin (16 mg/l) had much higher MIC90
values.
MSSA isolates
Ozenoxacin showed excellent activity (range ≤0.001–1 mg/l) against MSSA isolates (n = 247), with a MIC50 and
MIC90 of 0.004 mg/l. Only two isolates had a MIC for ozenoxacin above 0.25 mg/l (MIC of 1 mg/l). 14 MSSA
isolates were levofloxacin nonsusceptible (levofloxacin MIC50 = 4 mg/l and MIC90 ≥16 mg/l): the MIC50 and
MIC90 values for ozenoxacin against levofloxacin nonsusceptible MSSA isolates were 0.12 and 1 mg/l, respectively.
Lower MIC50 and MIC90 values (both 0.004 mg/l) were found for ozenoxacin against the 231 levofloxacin-
susceptible MSSA isolates (levofloxacin MIC50 = 0.25 mg/l and MIC90 = 0.25 mg/l; Table 1). Comparative
MIC data showed that ozenoxacin (MIC90 = 0.004 mg/l) was more active than all reference compounds against
MSSA isolates. The next most active compound was clindamycin (MIC90 = 0.12 mg/l) which was 30-fold less
active than ozenoxacin; followed by fusidic acid, mupirocin and retapamulin (MIC90 = 0.25 mg/l); daptomycin,
gentamicin, levofloxacin (MIC90 = 0.5 mg/l); ciprofloxacin, amoxicillin-clavulanate, tetracycline, vancomycin
(MIC90 = 1 mg/l); cefuroxime and linezolid (MIC90 = 2 mg/l); neomycin and ceftriaxone (MIC90 = 4 mg/l);
penicillin (MIC90 = 16 mg/l); and erythromycin (MIC90 = 64 mg/l; Table 1).
MRSA isolates
Ozenoxacin was highly active against MRSA isolates (n = 239), with a MIC50 of 0.12 mg/l and a MIC90 of
0.25 mg/l. One isolate had an ozenoxacin MIC of ≥4 mg/l, and five isolates from four different sites had an
ozenoxacin MIC of 2 mg/l. Eight strains of MRSA from seven sites had an ozenoxacin MIC of 1 mg/l. Ozenoxacin
future science group www.futuremedicine.com 5













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 Future Microbiol. (2018) 13(6s) future science group
Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates Supplement
had a MIC50 of 0.004 mg/l and a MIC90 of 0.008 mg/l for levofloxacin-susceptible MRSA isolates (n = 81;
levofloxacin MIC50 = 0.25 mg/l and MIC90 = 0.5 mg/l). A total of 154 MRSA isolates were also levofloxacin-
nonsusceptible (levofloxacin MIC50 = 8 mg/l and MIC90 ≥16 mg/l). Ozenoxacin had a MIC50 and a MIC90 of
0.12 and 0.25 mg/l, respectively, against levofloxacin-nonsusceptible MRSA isolates (Table 1). Comparative MIC90
data for all MRSA isolates tested showed that retapamulin (MIC90 = 0.12 mg/l) was the most active compound,
followed by ozenoxacin and fusidic acid (MIC90 = 0.25 mg/l); daptomycin (MIC90 = 0.5 mg/l); gentamicin
and vancomycin (MIC90 = 1 mg/l); linezolid (MIC90 = 2 mg/l); mupirocin (MIC90 = 8 mg/l); ciprofloxacin
(MIC90 ≥8 mg/l); levofloxacin (MIC90 ≥16 mg/l); amoxicillin-clavulanate and tetracycline (MIC90 = 32 mg/l);
penicillin (MIC90 = 64 mg/l); and ceftriaxone, cefuroxime, clindamycin, erythromycin and neomycin (MIC90
≥128 mg/l; Table 1). Ozenoxacin was significantly more potent (MIC90 = 0.008 mg/l) than all comparative
compounds for levofloxacin-susceptible MRSA isolates. It was 15-fold more active than retapamulin and fusidic
acid (MIC90 = 0.12 mg/l), with the rank order of other compounds being: mupirocin (MIC90 = 0.25 mg/l);
daptomycin and levofloxacin (MIC90 0.5 mg/l); ciprofloxacin; gentamicin and vancomycin (MIC90 = 1 mg/l);
linezolid (MIC90 = 2 mg/l); clindamycin and amoxicillin-clavulanate (MIC90 = 16 mg/l); cefuroxime and penicillin
(MIC90 = 32 mg/l); ceftriaxone, neomycin and tetracycline (MIC90 = 64 mg/l); and erythromycin (MIC90
≥128 mg/l; Table 1). Against MRSA isolates (n = 239), including those which were levofloxacin susceptible
(n = 81) and nonsusceptible (n = 154), ozenoxacin (MIC90 = 0.25 ug/ml) was 32-fold more active than mupirocin
(MIC90 = 8 μg/ml; Table 1).
Study 2
The antibacterial activity of ozenoxacin and comparators against S. aureus, stratified by methicillin and levofloxacin
susceptibility, is summarized in Table 2. Of the 504 S. aureus isolates included in the study, 225 (44.6%) were MRSA
and 279 (55.4%) were MSSA. Almost half (45.7%) of the MRSA isolates were also nonsusceptible to levofloxacin,
whereas only 6.5% of MSSA isolates were levofloxacin nonsusceptible. Ozenoxacin demonstrated excellent overall
activity (MIC50 = 0.002 mg/l, MIC90 = 0.06 mg/l) against all 504 S. aureus isolates, inhibiting 99.4% at a MIC
of ≤0.5 mg/l. The activity of ozenoxacin was higher against levofloxacin-susceptible S. aureus isolates (MIC50 and
MIC90 = 0.002 mg/l) compared with levofloxacin nonsusceptible isolates (MIC50 = 0.06 mg/l; MIC90 = 0.5 mg/l;
Table 2). MIC values to ozenoxacin in MRSA isolates (MIC50 = 0.004 mg/l; MIC90 = 0.12 mg/l) were slightly
higher than those found with all S. aureus isolates.
Ozenoxacin was the most potent agent against all S. aureus isolates tested. Comparing MIC50 values, ozenoxacin
(MIC50 = 0.002 mg/l) had 32-fold greater activity than clindamycin (MIC50 = 0.06 mg/l); 64-fold greater activity
than retapamulin or fusidic acid (MIC50 = 0.12 mg/l); and 128-fold greater activity than erythromycin, mupirocin,
ciprofloxacin or levofloxacin (MIC50 = 0.25 mg/l). At the MIC90 level, ozenoxacin (MIC90 = 0.06 mg/l) was twofold
more potent than retapamulin (MIC90 = 0.12 mg/l); fourfold more potent than fusidic acid (MIC90 = 0.25 mg/l);
eightfold more active than mupirocin (MIC90 = 0.5 mg/l); and at least 256-fold more potent than erythromycin,
clindamycin, ciprofloxacin or levofloxacin (MIC90 ≥16 mg/l; Table 2).
Against MRSA, ozenoxacin (MIC50 = 0.004 mg/l; MIC90 = 0.12 mg/l) had greater activity than mupirocin
(MIC50 = 0.25 mg/l; MIC90 = 0.5 mg/l) and fusidic acid (MIC50 = 0.12 mg/l; MIC90 = 0.25 mg/l), and using
MIC50 values, was more potent than retapamulin (MIC50 = 0.12 mg/l; MIC90 = 0.12 mg/l). Against levofloxacin
nonsusceptible S. aureus, ozenoxacin (MIC50 = 0.06 mg/l; MIC90 = 0.5 mg/l) had greater activity than mupirocin
(MIC50 = 0.25 mg/l; MIC90 = 2 mg/l) and fusidic acid (MIC50 = 0.12 mg/l; MIC90 = 0.25 mg/l), and was similar
to retapamulin using MIC50 values (Table 2). Whereas MIC50 values for clindamycin and ozenoxacin were both
0.06 mg/l, MIC90 values indicated that ozenoxacin (MIC90 = 0.5 mg/l) was at least 64-fold more potent than
clindamycin (MIC90 > 16 mg/l). The remaining agents had higher MIC50 and MIC90 values than ozenoxacin
(Table 2).
Table 3 shows the proportion of S. aureus, MSSA, MRSA and levofloxacin susceptible or resistant S. aureus isolates,
which were susceptible, resistant or had intermediate status to 11 antimicrobials, as assessed using EUCAST and
CLSI criteria. Up to approximately 7% of S. aureus, MRSA, and levofloxacin susceptible or resistant S. aureus
isolates were resistant to mupirocin and fusidic acid.
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Streptococcus species
S. pyogenes study 1
Ozenoxacin was highly active (range: 0.008–0.06 mg/l) against 217 S. pyogenes isolates, with a MIC50 of 0.03 mg/l
and a MIC90 of 0.06 mg/l. The most active compounds against S. pyogenes were cefuroxime (MIC90 ≤0.015 mg/l);
penicillin (MIC90 = 0.015 mg/l); ceftriaxone and amoxicillin-clavulanate (MIC90 = 0.03 mg/l); ozenoxacin, clin-
damycin, daptomycin, erythromycin and retapamulin (MIC90 = 0.06 mg/l); and mupirocin (MIC90 = 0.12 mg/l).
S. pyogenes isolates were less susceptible to ciprofloxacin and vancomycin (MIC90 = 0.5 mg/l); levofloxacin and
linezolid (MIC90 = 1 mg/l); fusidic acid and gentamicin (MIC90 = 8 mg/l); tetracycline (MIC90 = 32 mg/l); and
neomycin (MIC90 = 64 mg/l; Table 4). Thus, against S. pyogenes isolates ozenoxacin was equipotent to retapamulin,
had twofold higher activity than mupirocin and 13-fold higher activity than fusidic acid.
S. agalactiae study 1
Ozenoxacin was highly active (range: 0.008–0.06 mg/l) against the 37 S. agalactiae isolates tested, with a MIC50 of
0.03 mg/l and a MIC90 of 0.06 mg/l. Ozenoxacin, together with penicillin and retapamulin (MIC90 = 0.06 mg/l),
were the most active compounds against S. agalactiae. The rank order of the remaining compounds was: ceftriaxone,
cefuroxime and amoxicillin-clavulanate (MIC90 = 0.12 mg/l); daptomycin (MIC90 = 0.25 mg/l); vancomycin
(MIC90 = 0.5 mg/l); ciprofloxacin, levofloxacin and mupirocin (MIC90 = 1 mg/l); linezolid (MIC90 = 2 mg/l);
fusidic acid (MIC90 = 16 mg/l); gentamicin (MIC90 = 32 mg/l); tetracycline (MIC90 = 64 mg/l); clindamycin and
erythromycin (MIC90 ≥64 mg/l); and neomycin (MIC90 ≥128 mg/l; Table 4).
S. pneumoniae study 1
Ozenoxacin was highly active (range: 0.015–0.06 mg/l) against S. pneumoniae isolates (n = 29), with a MIC50
and MIC90 of 0.03 and 0.06 mg/l, respectively. In comparison to the reference compounds, ozenoxacin
(MIC90 = 0.06 mg/l) was significantly the most active. The rank order of the reference compounds was: dap-
tomycin (MIC90 = 0.25 mg/l); retapamulin and vancomycin (MIC90 = 0.5 mg/l); levofloxacin (MIC90 = 1 mg/l);
ceftriaxone, ciprofloxacin, linezolid and mupirocin (MIC90 = 2 mg/l); penicillin (MIC90 = 4 mg/l); amoxicillin-
clavulanate and gentamicin (MIC90 = 8 mg/l); cefuroxime (MIC90 = 16 mg/l); fusidic acid and tetracycline
(MIC90 = 32 mg/l); neomycin (MIC90 = 64 mg/l); and clindamycin and erythromycin (MIC90 ≥64 mg/l;
Table 4).
S. pyogenes & S. agalactiae study 2
The antibacterial activity of ozenoxacin and comparators against S. pyogenes (n = 124) and S. agalactiae (n = 88) is
summarized in Table 4. All isolates were susceptible to penicillin (MIC ≤0.12 mg/l), amoxicillin-clavulanate (MIC
≤4/2 mg/l) and vancomycin (MIC ≤0.5 mg/l). All S. pyogenes isolates and 95.5% (84/88) of S. agalactiae isolates
were susceptible to levofloxacin by CLSI interpretative criteria (Table 4). Ozenoxacin was highly active against both
S. pyogenes and S. agalactiae. MIC50 and MIC90 values were 0.008 and 0.015 mg/l, respectively, against S. pyogenes
and were 0.015 and 0.03 mg/l, respectively, against S. agalactiae (Table 4).
Ozenoxacin was the most potent (MIC50 = 0.008 mg/l; MIC90 = 0.015 mg/l) agent tested against all S. pyogenes
isolates, inhibiting 98.3% at a MIC of ≤0.03 mg/l. Ozenoxacin was fourfold more active than erythromycin,
clindamycin or retapamulin (MIC50 = 0.03 mg/l; MIC90 = 0.06 mg/l), at least eightfold more active than mupirocin
(MIC50 = 0.06 mg/l; MIC90 = 0.25 mg/l), 64-fold more active than ciprofloxacin or levofloxacin (MIC50 = 0.5 mg/l;
MIC90 = 1 mg/l) and at least 256-fold more active than fusidic acid (MIC50 and MIC90 = 4 mg/l; Table 4).
Ozenoxacin was also the most potent (MIC50 = 0.015 mg/l; MIC90 = 0.03 mg/l) agent tested against S. agalactiae
isolates, inhibiting 95.5% of isolates at a MIC of ≤0.03 mg/l. Ozenoxacin was at least twofold more active than
erythromycin or clindamycin (MIC50 = 0.03 mg/l; MIC90 >16 mg/l); fourfold more active than retapamulin
(MIC50 = 0.06 mg/l; MIC90 = 0.12 mg/l); 32-fold more active than ciprofloxacin or levofloxacin (MIC50 = mg/l;
MIC90 = 0.5/1 mg/l); at least 32-fold more active than mupirocin (MIC50 and MIC90 = 1 mg/l); and 512-fold
more active than fusidic acid (MIC50 = 8 mg/l; MIC90 = 16 mg/l; Table 4).
S. epidermidis study 1
MIC50 and MIC90 values for ozenoxacin and comparator antimicrobial agents against S. epidermidis isolates, which
were also stratified by methicillin and levofloxacin susceptibility, are shown in Table 5. Ozenoxacin was highly active
against S. epidermidis isolates (n = 190), with a MIC50 of 0.06 mg/l and a MIC90 of 1 mg/l. Two isolates from
different sites had an ozenoxacin MIC of ≥4 mg/l and 12 isolates from nine sites had an ozenoxacin MIC of 2 mg/l.
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Table 6. Study 2: MIC50 and MIC90 values for ozenoxacin and comparator antimicrobials against
Staphylococcus epidermidis stratified by methicillin and levofloxacin susceptibility.
MIC
(mg/l)
OZE MUP FUS RET LVX CIP AMC CLI ERY PEN VAN
S. epidermidis (n = 195; all) MIC50 0.008 0.25 0.12 0.06 0.25 0.5 ≤4/2 0.06 16 0.25 1
MIC90 0.25 256 8 0.25 16 16 8/4 16 16 0.25 2
MSSE (n = 86) MIC50 0.004 0.25 0.12 0.06 0.25 0.25 ≤4/2 0.06 16 0.25 1
MIC90 0.03 256 8 0.25 4 4 ≤4/2 0.12 16 0.25 2
MRSE (n = 109) MIC50 0.06 0.25 0.12 0.06 4 8 ≤4/2 0.25 16 0.25 1
MIC90 0.5 256 16 0.12 16 16 8/4 16 16 0.25 2
Levofloxacin susceptible S.
epidermidis (n = 105)
MIC50 0.004 0.25 0.12 0.06 0.25 0.25 ≤4/2 0.06 16 0.25 1
MIC90 0.008 256 4 0.25 0.25 0.5 ≤4/2 0.12 16 0.25 2
Levofloxacin nonsusceptible
S. epidermidis (n = 90)
MIC50 0.06 0.25 0.12 0.06 8 16 ≤4/2 16 16 0.25 1
MIC90 1 256 16 0.12 16 16 8/4 16 16 0.25 2
AMC: Amoxicillin-clavulanate; CIP: Ciprofloxacin; CLI: Clindamycin; ERY: Erythromycin; FUS: Fusidic acid; LVX: Levofloxacin; MIC: Minimum inhibitory
concentration; MRSE: Methicillin-resistant S. epidermidis; MSSE: Methicillin-susceptible S. epidermidis; MUP: Mupirocin; OZE: Ozenoxacin; PEN: Penicillin;
RET: Retapamulin; VAN: Vancomycin.
13 strains of S. epidermidis from ten sites had an ozenoxacin MIC of 1 mg/l (Table 5). Against all S. epidermidis
isolates tested (n = 190), retapamulin (MIC90 = 0.12 mg/l) was the most active compound. Ozenoxacin (MIC90 =
1 mg/l) was fourfold more active than fusidic acid (MIC90 = 4 mg/l) and more than 1000-fold more active than
mupirocin (MIC90 ≥1024 mg/l). Daptomycin (MIC90 = 0.5 mg/l) was the second most active compound tested
(Table 5).
Ozenoxacin was highly active against methicillin-susceptible S. epidermidis (MSSE) isolates (n = 64) with a
MIC50 of 0.008 mg/l and a MIC90 of 0.12 mg/l. 12 MSSE isolates were levofloxacin nonsusceptible (levofloxacin
MIC50 = 8 mg/l and MIC90 ≥ 16 mg/l): the ozenoxacin MIC50 and MIC90 were 0.12 and 1 mg/l, respectively.
An ozenoxacin MIC50 of 0.008 mg/l and a MIC90 of 0.015 mg/l were found for levofloxacin-susceptible MSSE
isolates (n = 51; levofloxacin MIC50 = 0.25 mg/l and MIC90 = 0.5 mg/l; Table 5).
Ozenoxacin was highly active against methicillin-resistant S. epidermidis (MRSE) isolates (n = 126), with a
MIC50 of 0.12 mg/l and a MIC90 of 2 mg/l. For levofloxacin nonsusceptible S. epidermidis isolates (n = 97;
levofloxacin MIC50 ≥16 mg/l and MIC90 ≥16 mg/l) the ozenoxacin MIC50 was 0.12 mg/l and the MIC90
was 2 mg/l. Ozenoxacin was much more active against levofloxacin-susceptible S. epidermidis isolates (n = 92;
levofloxacin MIC50 = 0.25 mg/l and MIC90 = 0.25 mg/l), with MIC50 and MIC90 values of 0.008 and 0.015 mg/l,
respectively (Table 5). Against levofloxacin susceptible S. epidermidis (n = 92), including MSSE (n = 51) and MRSE
(n = 41), ozenoxacin (MIC90 = 0.015 mg/l against all isolates) was at least eightfold more active than retapamulin
(MIC90 = 0.12, 0.12 and 0.25 mg/l, respectively) and at least 128-fold more active than fusidic acid (MIC90 = 2, 4
and 0.25 mg/l, respectively). The respective MIC90 values of mupirocin against this group of isolates were ≥1024,
256 and ≥1024 mg/l (Table 5).
S. epidermidis study 2
The antibacterial activity of ozenoxacin and comparators against S. epidermidis, stratified by methicillin and
levofloxacin susceptibility, is shown in Table 6. Of the 195 S. epidermidis isolates included in the study, 109
(55.9%) were methicillin-resistant and 86 (44.1%) were methicillin-susceptible. Levofloxacin resistance among
MRSE and MSSE isolates was 72.5 and 12.8%, respectively (Table 6). Ozenoxacin was the most potent agent
tested against S. epidermidis (MIC50 = 0.008; MIC90 = 0.25 mg/l), in common with data for all coagulase-negative
staphylococci isolates. The activity of ozenoxacin was higher against MSSE isolates (n = 86; MIC50 = 0.004;
MIC90 = 0.03) than against MRSE isolates (n = 109; MIC50 = 0.06; MIC90 = 0.5). The activity of ozenoxacin
was also higher against levofloxacin-susceptible S. epidermidis isolates (n = 105; MIC50 = 0.004; MIC90 = 0.008)
than against levofloxacin nonsusceptible S. epidermidis isolates (n = 90; MIC50 = 0.06; MIC90 = 1) regardless of
the methicillin resistance status (Table 6).
Comparative analyses of MIC50 values against S. epidermidis showed that ozenoxacin (MIC50 = 0.008 mg/l) had
eightfold greater activity than clindamycin and retapamulin (MIC50 = 0.06 mg/l); 16-fold greater activity than
fusidic acid (MIC50 = 0.12 mg/l); 32-fold greater activity than mupirocin or levofloxacin (MIC50 = 0.25 mg/l);
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64-fold greater activity than ciprofloxacin (MIC50 = 0.5 mg/l); and at least greater than 256-fold greater activity
than erythromycin (MIC50 >16 mg/l; Table 6).
Against levofloxacin nonsusceptible S. epidermidis isolates, retapamulin (MIC50 = 0.06 mg/l; MIC90 = 0.12 mg/l)
was the most active antimicrobial agent tested, with ozenoxacin (MIC50 = 0.06 mg/l; MIC90 = 1 mg/l) ranked
second in potency of all tested compounds (Table 6).
Ozenoxacin had higher activity against MRSE (MIC50 = 0.06 mg/l; MIC90 = 0.5 mg/l) than mupirocin
(MIC50 = 0.25 mg/l; MIC90 >256 mg/l) and fusidic acid (MIC50 = 0.12 mg/l; MIC90 = 16 mg/l). Against
levofloxacin nonsusceptible S. epidermidis, ozenoxacin (MIC50 = 0.06 mg/l; MIC90 = 1 mg/l) was more potent
than mupirocin (MIC50 = 0.25 mg/l; MIC90 >256 mg/l) and fusidic acid (MIC50 = 0.12 mg/l; MIC90 = 16 mg/l;
Table 6).
CNS species other than S. epidermidis: study 1
For CNS spp. which were not strains of S. epidermidis (n = 37), oxenoxacin was more active than all reference
compounds with an MIC50 of 0.008 mg/l and a MIC90 of 0.12 mg/l. In comparison, the rank order of reference
compounds was daptomycin (MIC90 = 0.5 mg/l); linezolid (MIC90 = 1 mg/l); neomycin, retapamulin and van-
comycin (MIC90 = 2 mg/l); gentamicin and tetracycline (MIC90 = 4 mg/l); ciprofloxacin, amoxicillin-clavulanate
and levofloxacin (MIC90 = 8 mg/l); fusidic acid and penicillin (MIC90 = 16 mg/l); ceftriaxone and cefuroxime
(MIC90 = 64 mg/l); clindamycin and erythromycin (MIC90 ≥128 mg/l); and mupirocin (MIC90 ≥1024 mg/l;
Table 7).
CNS species other than S. epidermidis: study 2
Table 7 summarizes the antibacterial activity of ozenoxacin and comparators against CNS, stratified by methicillin
and levofloxacin susceptibility. Of the 315 CNS isolates included in the study, 146 (46.3%) were methicillin-
resistant (MR-CNS) and 169 (53.7%) were methicillin-susceptible (MS-CNS). Most of the MR-CNS isolates
(72.6%) were nonsusceptible to levofloxacin, compared with only 8.3% of the MS-CNS isolates. Ozenoxacin was
highly active against all CNS isolates (MIC50 = 0.008 mg/l; MIC90 = 0.12 mg/l) inhibiting 96.8% of isolates at
a MIC of ≤0.5 mg/l. Ozenoxacin tested against levofloxacin-nonsusceptible CNS isolates (MIC50 = 0.06 mg/l;
MIC90 = 0.5 mg/l) showed MIC values at least 16-fold higher than isolates with levofloxacin susceptibility
(MIC50 = 0.004 mg/l; MIC90 = 0.008 mg/l). Similar results were obtained for MR-CNS (MIC50 = 0.06 mg/l;
MIC90 = 0.5 mg/l) compared with MS-CNS (MIC50 = 0.004 mg/l; MIC90 = 0.015 mg/l; Table 7). These
differences were due to quinolone cross-resistance rather than methicillin-susceptibility, because levofloxacin-
susceptible MR-CNS isolates had lower MIC90 values (MIC50 = 0.004 mg/l; MIC90 = 0.008 mg/l; Table 7).
Ozenoxacin had higher activity against methicillin-resistant CNS isolates and levofloxacin nonsusceptible CNS
isolates (MIC50 = 0.06 mg/l and MIC90 = 0.5 mg/l against both) than mupirocin (MIC50 = 0.25 mg/l and MIC90
>256 mg/l against both) and fusidic acid (MIC50 = 0.12 mg/l and MIC90 = 0.16 mg/l against both; Table 7).
Corynebacterium species (study 1)
The range of ozenoxacin against Corynebacterium species was 0.008 to ≥4 mg/l, with a MIC50 of 1 mg/l. This
activity was considerably greater than that of ciprofloxacin (MIC50 = 8 mg/l) and levofloxacin (MIC50 = 16 mg/l).
Ozenoxacin (MIC90 of ≥4 mg/l) was less active than daptomycin and vancomycin (MIC90 = 0.5 mg/l), and fusidic
acid, linezolid and retapamulin (MIC90 = 1 mg/l), against Corynebacterium species.
Ozenoxacin was significantly more potent (MIC90 = 0.06 mg/l) than all reference compounds for levofloxacin-
susceptible isolates of Corynebacterium species. By comparison, the rank order for reference compounds was
gentamicin (MIC90 = 0.25 mg/l); daptomycin and fusidic acid (MIC90 = 0.5 mg/l); ciprofloxacin, levofloxacin,
linezolid, neomycin, retapamulin and vancomycin (MIC90 = 1 mg/l); cefuroxime and amoxicillin-clavulanate
(MIC90 = 8 mg/l); ceftriaxone and erythromycin (MIC90 = 16 mg/l); penicillin and tetracycline (MIC90 = 32 mg/l);
mupirocin (MIC90 = 128 mg/l) and clindamycin (MIC90 ≥128 mg/l).
Other isolates including Micrococcus & Lactobacillus species (study 1)
A small number of other strains were evaluated for ozenoxacin susceptibility in study 1. The MIC range of
ozenoxacin was 0.004–0.06 mg/l for Micrococcus spp. (n = 7); 0.008–0.25 mg/l for Group G Streptococcus spp.
(n = 19); 0.008–0.03 mg/l for Group C Streptococcus spp. (n = 9); 0.03–1 mg/l for Brevibacterium spp. (n = 3);
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Table 8. Comparison of ozenoxacin MIC50 and MIC90 values in studies 1 and 2.
Microorganism isolate Study 1 Study 2
n MIC50 MIC90 n MIC50 MIC90
S. aureus (all) 486 0.004 0.25 504 0.002 0.06
MSSA 247 0.004 0.004 279 0.002 0.004
MRSA 239 0.12 0.25 225 0.004 0.12
Levofloxacin-susceptible S. aureus 312 0.004 0.004 383 0.002 0.002
Levofloxacin-nonsusceptible S. aureus 168 0.12 0.5 121 0.06 0.5
Levofloxacin-nonsusceptible MSSA 14 0.12 1 18 0.06 0.12
Levofloxacin-susceptible MSSA 231 0.004 0.004 261 0.002 0.002
Levofloxacin-susceptible MRSA 81 0.004 0.008 122 0.002 0.002
Levofloxacin-nonsusceptible MRSA 154 0.12 0.25 103 0.06 0.5
Streptococcus pyogenes 217 0.03 0.06 124 0.008 0.015
Streptococcus agalactiae 37 0.03 0.06 88 0.015 0.03
Streptococcus pneumoniae 29 0.03 0.06
S. epidermidis (all) 190 0.06 1 195 0.008 0.25
MSSE 64 0.008 0.12 86 0.004 0.03
MRSE 126 0.12 2 109 0.06 0.5
Levofloxacin-susceptible S. epidermidis 92 0.008 0.015 105 0.004 0.008
Levofloxacin-nonsusceptible S. epidermidis 97 0.12 2 90 0.06 1
Levofloxacin-nonsusceptible, MSSE 12 0.12 1 11 0.06 0.5
Levofloxacin-nonsusceptible, MRSE 85 0.12 2 79 0.06 1
Levofloxacin-susceptible, MRSE 41 0.008 0.015 30 0.004 0.008
Levofloxacin-susceptible, MSSE 51 0.008 0.015 75 0.004 0.004
CNS (all) 37 0.008 0.12 315 0.008 0.12
Methicillin-susceptible CNS 169 0.004 0.015
Methicillin-resistant CNS 146 0.06 0.5
Levofloxacin-susceptible CNS 195 0.004 0.008
Levofloxacin-nonsusceptible CNS 120 0.06 0.5
Corynebacterium species (all) 52 1 ≥4
Levofloxacin-resistant Corynebacterium species 35 2 ≥4
Levofloxacin-susceptible Corynebacterium species 17 0.015 0.06
CNS: Coagulase-negative Staphylococcus species; MRSA: Methicillin-resistant S. aureus; MRSE: Methicillin-resistant S. epidermidis; MSSA: Methicillin-susceptible S. aureus;
MSSE: Methicillin-susceptible S. epidermidis.
0.03–2 mg/l for Enterococcus faecalis (n = 2); 0.03–2 mg/l for Kocuria kristinae (n = 1); and 0.015 mg/l for R.
mucilaginosa (n = 1).
Comparison between study 1 & study 2
An overall summary comparing ozenoxacin MIC50 and MIC90 values in S. aureus, Streptococcus spp., S. epidermidis,
coagulase-negative staphylococci and Corynebacterium spp. in both studies (Table 8) showed good general agreement.
Discussion
Clinical isolates were collected and analyzed for susceptibility or resistance to a panel of antimicrobial agents in
two in vitro studies. The first collection of 1097 isolates from 49 centers was made during 2009–2010, and a later
collection of 1031 clinical isolates at ten centers was made during 2014. S. aureus isolates predominated in both
collections accounting for 44 and 49% of all isolates, respectively. S. aureus and S. epidermidis isolates were stratified
by methicillin and levofloxacin resistance/susceptibility status. The antibacterial effects of ozenoxacin determined
using MIC50 and MIC90 values were compared with 17 and ten antimicrobial agents, respectively. These included
the topical agents mupirocin, fusidic acid and retapamulin, and also other antimicrobials for comparative activity
against resistant and susceptible strains.
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Ozenoxacin was the most potent agent tested against all S. aureus isolates. At the MIC90 level, ozenoxacin
(MIC90 = 0.06 mg/l) was twofold more potent than retapamulin (MIC90 = 0.12 mg/l), fourfold more potent than
fusidic acid (MIC90 = 0.25 mg/l), eightfold more active than mupirocin (MIC90 = 0.5 mg/l) and at least 256-fold
more potent than erythromycin, clindamycin, ciprofloxacin or levofloxacin (MIC90 ≥16 mg/l for all; study 2 data).
Tested against levofloxacin nonsusceptible S. aureus isolates, ozenoxacin (MIC50/90, 0.06/0.5 mg/l) was also the
most potent compound. Only clindamycin had an MIC50 (0.06 mg/l) equal to that of ozenoxacin. The remaining
agents had higher MIC50 and MIC90 values than ozenoxacin (study 2 data).
Methicillin-resistant staphylococci had raised MICs to ozenoxacin, but this was due to quinolone cross-resistance
rather than methicillin susceptibility, as levofloxacin-susceptible but methicillin-resistant staphylococci had an
ozenoxacin MIC90 of 0.002 against S. aureus and 0.008 mg/l against coagulase-negative staphylococci (study 2 data).
Compared with staphylococcal isolates with susceptibility to levofloxacin, ozenoxacin had lower activity when tested
against levofloxacin nonsusceptible staphylococci with MIC50 and MIC90 values of 0.06 and 0.5 mg/l, respectively
(study 2 data). This clearly high intrinsic activity in levofloxacin nonsusceptible isolates was also addressed in a
previous study in which the presence of GyrA and ParC amino acid substitutions were characterized [16]. Interestingly,
only isolates with double mutations in both GyrA and ParC had ozenoxacin MIC values higher than 0.5 mg/l.
The percentage of S. aureus displaying MIC values more than 0.5 mg/l in study 2 was only 0.6%.
Comparison of ozenoxacin MIC50 and MIC90 values for isolates collected in the two studies showed good general
agreement and differences between study 1 and study 2 may reflect differences in the diversity of clinical isolates.
A previous study of ozenoxacin susceptibility performed in Japan reported MIC90 values for ozenoxacin against
MSSA, MRSA and S. pyogenes isolates obtained from clinical cutaneous specimens of ≤0.06, 4 and ≤0.06 mg/l,
respectively. There was no difference between ozenoxacin MIC90 values for MSSA and S. pyogenes isolates obtained
from adults and children, but the ozenoxacin MIC90 (0.12 μg/ml) against pediatric MRSA isolates was 32-fold
lower than that found for adult isolates [17]. This could be due to the impact of fluoroquinolone use in adults.
In comparison, in the present studies, ozenoxacin MIC90 values were 0.004 mg/l in both studies 1 and 2 against
MSSA; 0.25 and 0.12 mg/l in study 1 and study 2, respectively, against MRSA; and 0.06 and 0.015 mg/l in study
1 and study 2, respectively, against S. pyogenes.
A second Japanese study of the antimicrobial activity of ozenoxacin against isolates from patients with acne vulgaris
reported MIC90 values of ozenoxacin against S. aureus, S. epidermidis and other coagulase-negative staphylococci
of ≤0.06, 0.125 and ≤0.06 mg/l, respectively [18]. In comparison, in the present studies, ozenoxacin MIC90 values
were 0.25 and 0.06 mg/l in study 1 and study 2, respectively, against S. aureus; 1 and 0. 25 mg/l in study 1
and study 2, respectively, against S. epidermidis; and 0.12 mg/l in both studies 1 and 2 against coagulase-negative
staphylococci. The MIC90 of ozenoxacin against Propionibacterium acnes was ≤0.06 mg/l in the Japanese study [18],
but strains of this species were not included in the present study.
Conclusion
Ozenoxacin is a potent antimicrobial agent against both staphylococci and streptococci, irrespective of levofloxacin
susceptibility status.
Future perspective
The in vitro spectrum of activity of ozenoxacin against staphylococci and streptococci, irrespective of methicillin
or levofloxacin susceptibility, is mirrored by the efficacy of ozenoxacin in a clinical setting for the treatment
of impetigo. Phase III trials showed that ozenoxacin produced a statistically significant superior microbiological
response compared with placebo [7,8], and had comparable efficacy to retapamulin but with a higher microbiological
clearance rate [7]. These results support future ozenoxacin use and inclusion in impetigo guidelines.
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Executive summary
• The in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial agents against
Gram-positive clinical isolates obtained from skin and soft tissue infections were compared.
• Isolates were collected in two studies: 1097 isolates from 49 centers during 2009–2010 in study 1 and 1031 isolates
from ten centers during 2014 in study 2. The antibacterial effects of ozenoxacin were compared with 17 and ten
antimicrobial agents in studies 1 and 2, respectively, by using MICs. Isolates were stratified by species and
methicillin susceptibility/resistance and/or levofloxacin susceptibility/nonsusceptibility status.
• Comparison of ozenoxacin MIC50 and MIC90 values for isolates collected in both studies showed good general
agreement. Overall, ozenoxacin was the most potent antimicrobial agent tested against staphylococci and
streptococci. Ozenoxacin exhibited high in vitro activity against Staphylococcus aureus (MIC90 = 0.06 mg/l;
n = 504) and coagulase-negative staphylococci isolates in both studies (study 2 data: MIC90 = 0.12 mg/l; n = 315).
Ozenoxacin was also highly active against Streptococcus pyogenes (MIC90 = 0.015 mg/l; n = 217) and
Streptococcus agalactiae (MIC90 = 0.03 mg/l; n = 88) isolates.
• In conclusion, ozenoxacin is a potent antimicrobial agent against staphylococci and streptococci, major
pathogens involved in impetigo.
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